Companies · Pharma
ALAMEDA · Pharma · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on Mimosa Therapeutics, A Public Benefit Corp — recommendation, valuation, rhythm, risks.→Mimosa Therapeutics, A Public Benefit Corp looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Mimosa Therapeutics, A Public Benefit Corp is one of 310 Pharma companies tracked from ALAMEDA. By capital raised it ranks in the long tail (ahead of 38% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 38% of sector peers (real $). Modeled value above 35% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 20.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Jupiter Therapeutics, Inc. | Pre-Seed | $1.0M | $47.3M | 3.52× |
| Tavros Therapeutics, Inc. | Pre-Seed | $1000K | $47.3M | 3.52× |
| Kalytera Therapeutics, Inc. | Pre-Seed | $2.2M | $35.9M | 2.67× |
| Veterinary Radiation Oncology of the Chesapeake, LLC | Pre-Seed | $925K | $29.6M | 2.20× |
| Chamishi Therapeutics, Inc. | Pre-Seed | $490K | $23.2M | 1.73× |
| Ikaika Therapeutics, Inc. | Pre-Seed | $1.0M | $22.5M | 1.67× |
| Organoid Therapeutics, Inc. | Pre-Seed | $445K | $21.0M | 1.57× |
| Mindset Pharma Inc. | Pre-Seed | $694K | $20.7M | 1.54× |
| Neurexis Therapeutics, Inc. | Pre-Seed | $500K | $16.1M | 1.20× |
| Hyka Therapeutics Inc. | Pre-Seed | $307K | $14.5M | 1.08× |
| Chekkit | Pre-Seed | $500K | $12.3M | 0.92× |
| Naturomed Therapeutics, Ltd. | Pre-Seed | $585K | $12.0M | 0.90× |
| Mimosa Therapeutics, A Public Benefit Corp this company | Pre-Seed | $1.3M | $10.5M | 0.78× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $865K | 2021-02-09 | $4.8M | $28.6M | 90% |
| Pre-Seed | $400K | 2021-07-01 | $2.2M | $10.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Robert Stanley | — | 1 other | 2021-02 |
| Amanda Feilding | — | — | 2021-02 |
| James Keim | — | — | 2021-02 |
| Stephen Apkon | — | — | 2021-02 |
Mimosa Therapeutics, A Public Benefit Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Acanna Therapeutics, Inc. | Pharma | Pre-Seed | $1.0M | $16.1M | same sector · same stage |
| Ikaika Therapeutics, Inc. | Pharma | Pre-Seed | $1.0M | $22.5M | same sector · same stage |
| Jupiter Therapeutics, Inc. | Pharma | Pre-Seed | $1.0M | $47.3M | same sector · same stage |
| Tavros Therapeutics, Inc. | Pharma | Pre-Seed | $1000K | $47.3M | same sector · same stage |
| vivo-TIL Therapeutics, Inc | Pharma | Pre-Seed | $990K | $46.8M | same sector · same stage |
| UVLrx Therapeutics, Inc. | Pharma | Pre-Seed | $980K | $9.7M | same sector · same stage |
| Protibea Therapeutics, Inc. | Pharma | Pre-Seed | $970K | $481K | same sector · same stage |
| JSK Therapeutics, Inc. | Pharma | Pre-Seed | $963K | $45.5M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Mizar Therapeutics, Inc. | Pharma | Pre-Seed | $1.4M | 81% |
| Mirador Therapeutics, Inc. | Pharma | Series D+ | $4.0B | 77% |
| PiVista Therapeutics, Inc. | Pharma | Pre-Seed | $2.5M | 77% |
| FloSpine Holdings, Inc. | Other Health Care | Pre-Seed | $409K | 77% |
| Cyana Therapeutics, LLC | Pharma | Pre-Seed | $300K | 76% |
| Synereca Pharmaceuticals, Inc. | Biotech / Pharma | Pre-Seed | $30.7M | 76% |
| Cyrano Therapeutics, Inc. | Pharma | Series A | $108.4M | 76% |
| Convelo Therapeutics, Inc. | Pharma | Series A | $113.3M | 75% |
See where Mimosa Therapeutics, A Public Benefit Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Mimosa Therapeutics, A Public Benefit Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.